

Manuel Muñoz-Torres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7010807/publications.pdf>

Version: 2024-02-01

136
papers

4,891
citations

94269

37
h-index

110170

64
g-index

165
all docs

165
docs citations

165
times ranked

5164
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D and COVID-19: where are we now?. <i>Postgraduate Medicine</i> , 2023, 135, 195-207.	0.9	7
2	Identification of Potential Targets Linked to the Cardiovascular/Alzheimer's Axis through Bioinformatics Approaches. <i>Biomedicines</i> , 2022, 10, 389.	1.4	2
3	Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia. <i>Frontiers in Endocrinology</i> , 2022, 13, 863940.	1.5	1
4	Evaluation of Quality and Bone Microstructure Alterations in Patients with Type 2 Diabetes: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 2206.	1.0	10
5	Position of the Spanish Society of Rheumatology (SER) and the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM) on romosozumab. <i>Reumatología Clínica (English Edition)</i> , 2022, , .	0.2	0
6	The Contribution of Wnt Signaling to Vascular Complications in Type 2 Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6995.	1.8	6
7	3D DXA Hip Differences in Patients with Acromegaly or Adult Growth Hormone Deficiency. <i>Journal of Clinical Medicine</i> , 2021, 10, 657.	1.0	3
8	Hypophosphatasia: A Unique Disorder of Bone Mineralization. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4303.	1.8	30
9	Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2209.	1.0	5
10	Thyroid function is not associated with brown adipose tissue volume and 18F-fluorodeoxyglucose uptake in young euthyroid adults. <i>European Journal of Endocrinology</i> , 2021, 185, 209-218.	1.9	4
11	Lower trabecular bone score in type 2 diabetes mellitus: A role for fat mass and insulin resistance beyond hyperglycaemia. <i>Diabetes and Metabolism</i> , 2021, 47, 101276.	1.4	14
12	Mobile and Wearable Technology for the Monitoring of Diabetes-Related Parameters: Systematic Review. <i>JMIR MHealth and UHealth</i> , 2021, 9, e25138.	1.8	43
13	Mechanisms Involved in the Relationship between Vitamin D and Insulin Resistance: Impact on Clinical Practice. <i>Nutrients</i> , 2021, 13, 3491.	1.7	52
14	Analysis of Bone Impairment by 3D DXA Hip Measures in Patients With Primary Hyperparathyroidism: A Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 175-184.	1.8	10
15	Nuevas tecnologías en la evaluación de la fragilidad ósea y su aplicación en Endocrinología. <i>Endocrinología, Diabetes Y Nutrición</i> , 2020, 67, 602-610.	0.1	1
16	Association between oxidative-stress-related markers and calcified femoral artery in type 2 diabetes patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 190, 113535.	1.4	7
17	Nutrients and Dietary Patterns Related to Osteoporosis. <i>Nutrients</i> , 2020, 12, 1986.	1.7	107
18	Circulating Undercarboxylated Osteocalcin as Estimator of Cardiovascular and Type 2 Diabetes Risk in Metabolic Syndrome Patients. <i>Scientific Reports</i> , 2020, 10, 1840.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets. <i>Advances in Therapy</i> , 2020, 37, 121-126.	1.3	2
20	Trastornos del fosfato y actitud cl�nica ante situaciones de hipofosfatemia e hiperfosfatemia. <i>Endocrinolog�a, Diabetes Y Nutrici�n</i> , 2020, 67, 205-215.	0.1	11
21	Usefulness of Trabecular Bone Score (TBS) to Identify Bone Fragility in Patients with Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2019, 22, 162-170.	0.5	30
22	Epidemiological, Clinical and Genetic Study of Hypophosphatasia in A Spanish Population: Identification of Two Novel Mutations in The <i>Alpl</i> Gene. <i>Scientific Reports</i> , 2019, 9, 9569.	1.6	24
23	Factors Predicting the Response to a Vitamin D-Fortified Milk in Healthy Postmenopausal Women. <i>Nutrients</i> , 2019, 11, 2641.	1.7	4
24	Vitamin D Status, Calcium Intake and Risk of Developing Type 2 Diabetes: An Unresolved Issue. <i>Nutrients</i> , 2019, 11, 642.	1.7	56
25	The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. <i>Endocrine</i> , 2019, 64, 441-455.	1.1	22
26	The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. <i>Osteoporosis International</i> , 2019, 30, 71-78.	1.3	13
27	Osteoporosis y psoriasis. <i>Actas Dermo-sifilogr�ficas</i> , 2019, 110, 642-652.	0.2	11
28	Effects of Daily Intake of Calcium and Vitamin D-Enriched Milk in Healthy Postmenopausal Women: A Randomized, Controlled, Double-Blind Nutritional Study. <i>Journal of Women's Health</i> , 2018, 27, 561-568.	1.5	30
29	Hiperparatiroidismo primario. <i>Medicina Cl�nica</i> , 2018, 150, 226-232.	0.3	16
30	Spanish consensus on treat to target for osteoporosis. <i>Osteoporosis International</i> , 2018, 29, 489-499.	1.3	13
31	Identificaci�n de hipofosfatasa en la pr�ctica cl�nica: manifestaciones cl�nicas y recomendaciones diagn�sticas en pacientes adultos. <i>Medicina Cl�nica</i> , 2018, 150, 75-79.	0.3	6
32	High Irisin levels in nondiabetic HIV-infected males are associated with insulin resistance, nonalcoholic fatty liver disease, and subclinical atherosclerosis. <i>Clinical Endocrinology</i> , 2018, 89, 414-423.	1.2	18
33	Circulating levels of sclerostin are associated with cardiovascular mortality. <i>PLoS ONE</i> , 2018, 13, e0199504.	1.1	41
34	Consensus document on osteoporosis in males. <i>Endocrinolog�a Diabetes Y Nutrici�n (English Ed)</i> , 2018, 65, 9-16.	0.1	0
35	Higher Levels of Serum 25-Hydroxyvitamin D Are Related to Improved Glucose Homeostasis in Women with Postmenopausal Osteoporosis. <i>Journal of Women's Health</i> , 2018, 27, 1007-1015.	1.5	4
36	Recomendaciones sobre el efecto de los f�rmacos antidiab�ticos en el hueso. <i>Endocrinolog�a, Diabetes Y Nutrici�n</i> , 2017, 64, 1-6.	0.1	4

#	ARTICLE	IF	CITATIONS
37	Recommended vitamin D levels in the general population. <i>Endocrinología Y Nutrición (English Ed)</i> , 2017, 64, 7-14.	0.1	10
38	Recommendations on the effect of antidiabetic drugs in bone. <i>Endocrinología Y Nutrición (English Ed)</i> , 2017, 64, 1-6.	0.1	1
39	SNPs in bone-related miRNAs are associated with the osteoporotic phenotype. <i>Scientific Reports</i> , 2017, 7, 516.	1.6	17
40	Ensayos clínicos de resultados de enfermedad cardiovascular en diabetes. <i>Endocrinología Y Nutrición: Organo De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2016, 63, 317-319.	0.8	3
41	Daily Intake of Milk Enriched with n-3 Fatty Acids, Oleic Acid, and Calcium Improves Metabolic and Bone Biomarkers in Postmenopausal Women. <i>Journal of the American College of Nutrition</i> , 2016, 35, 529-536.	1.1	30
42	Results from Cardiovascular Outcome Trials in Diabetes. <i>Endocrinología Y Nutrición (English)</i> 10 Tf 50 54.	0.5	1
43	Validation of PHPQoL, a Disease-Specific Quality-of-Life Questionnaire for Patients With Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1571-1578.	1.8	27
44	Metabolomic profile related to cardiovascular disease in patients with type 2 diabetes mellitus: A pilot study. <i>Talanta</i> , 2016, 148, 135-143.	2.9	44
45	Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?. <i>Endocrine</i> , 2016, 52, 54-62.	1.1	40
46	Dickkopf1 (DKK1), metabolismo óseo y enfermedad aterosclerótica en pacientes con diabetes mellitus tipo 2. <i>Revista De Osteoporosis Y Metabolismo Mineral</i> , 2016, 8, 24-29.	0.3	3
47	Relationship between Proinflammatory and Antioxidant Proteins with the Severity of Cardiovascular Disease in Type 2 Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2015, 16, 9469-9483.	1.8	17
48	Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 202-206.	2.2	32
49	Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis. <i>Maturitas</i> , 2015, 82, 402-410.	1.0	7
50	Pseudohypoparathyroidism Type 1b Associated with Novel Duplications in the GNAS Locus. <i>PLoS ONE</i> , 2015, 10, e0117691.	1.1	20
51	Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis. <i>PLoS Pathogens</i> , 2015, 11, e1004942.	2.1	63
52	Relationship of Dickkopf1 (DKK1) with Cardiovascular Disease and Bone Metabolism in Caucasian Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2014, 9, e111703.	1.1	35
53	Factores de riesgo cardiovascular en pacientes con hiperparatiroidismo primario asintomático. <i>Endocrinología Y Nutrición: Organo De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2014, 61, 516-522.	0.8	7
54	FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease. <i>Diabetes Care</i> , 2014, 37, e89-e90.	4.3	28

#	ARTICLE	IF	CITATIONS
55	Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. <i>Osteoporosis International</i> , 2014, 25, 645-651.	1.3	36
56	Bone turnover markers in patients with prostate carcinoma: influence of sex steroids levels. <i>Journal of Bone and Mineral Metabolism</i> , 2014, 32, 65-70.	1.3	5
57	Degludec, una nueva insulina basal de acción ultra-lenta para el tratamiento de la diabetes tipo 1 y 2: avances en investigación clínica. <i>Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición</i> , 2014, 61, 153-159.	0.8	2
58	The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. <i>European Journal of Endocrinology</i> , 2014, 171, 727-735.	1.9	43
59	Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: Advances in clinical research. <i>Endocrinología Y Nutrición (English Edition)</i> , 2014, 61, 153-159.	0.5	2
60	El hueso como órgano endocrino y su conexión con el metabolismo energético. , 2014, , 43-51.		0
61	El hueso en la diabetes mellitus. , 2014, , 63-73.		0
62	Consensus document for the detection and management of chronic kidney disease. <i>Nefrología</i> , 2014, 34, 243-62.	0.2	61
63	Development of a new tool for assessing Health-Related Quality of Life in patients with primary hyperparathyroidism. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 97.	1.0	33
64	Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente con diabetes mellitus. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición. <i>Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición</i> , 2013, 60, 517.e1-517.e18.	0.8	22
65	Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2013, 24, 1503-1511.	1.3	12
66	SHBG levels are associated with bone loss and vertebral fractures in patients with prostate cancer. <i>Osteoporosis International</i> , 2013, 24, 713-719.	1.3	15
67	Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. <i>Acta Diabetologica</i> , 2013, 50, 47-52.	1.2	65
68	Vitamin D hormone system and diabetes mellitus: Lessons from selective activators of vitamin D receptor and diabetes mellitus. <i>Endocrinología Y Nutrición (English Edition)</i> , 2013, 60, 87-95.	0.5	2
69	Osteocalcina: nexo de unión entre homeostasis ósea y metabolismo energético. <i>Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición</i> , 2013, 60, 260-263.	0.8	7
70	Osteocalcin: A link between bone homeostasis and energy metabolism. <i>Endocrinología Y Nutrición (English Edition)</i> , 2013, 60, 260-263.	0.5	8
71	Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels. <i>Diabetes Care</i> , 2013, 36, 1667-1674.	4.3	107
72	Gonadotropins Are Related to Lean Mass in Healthy Postmenopausal Women. <i>Endocrine Research</i> , 2013, 38, 119-124.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Ischemic heart disease is associated with vertebral fractures in patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2013, 4, 310-315.	1.1	10
74	Nicotinamide Inhibits the Lysosomal Cathepsin b-like Protease and Kills African Trypanosomes. <i>Journal of Biological Chemistry</i> , 2013, 288, 10548-10557.	1.6	25
75	Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 16-20.	1.8	10
76	Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 234-241.	1.8	259
77	Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. <i>European Journal of Endocrinology</i> , 2012, 167, 453.	1.9	25
78	Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate. <i>Menopause</i> , 2012, 19, 172-177.	0.8	11
79	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. <i>Lancet, The</i> , 2012, 379, 1498-1507.	6.3	304
80	An unusual association of neuroendocrine tumors in MEN 1A. <i>Pituitary</i> , 2012, 15, 393-397.	1.6	3
81	Vacaciones terapéuticas en pacientes con osteoporosis posmenopáusica: ¿a quién y cuándo?. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2012, 59, 573-574.	0.8	0
82	Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. <i>European Journal of Endocrinology</i> , 2012, 167, 287-294.	1.9	49
83	Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2012, 38, 76-81.	1.4	41
84	Clinical practice guidelines for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. <i>Endocrinología Y Nutrición (English Edition)</i> , 2012, 59, 174-196.	0.5	8
85	Serum Osteoprotegerin and Sex Steroid Levels in Patients With Prostate Cancer. <i>Journal of Andrology</i> , 2012, 33, 594-600.	2.0	6
86	Diagnosis and management of bilateral diaphyseal femoral fracture. <i>Endocrine</i> , 2012, 42, 451-452.	1.1	1
87	Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. <i>Endocrine</i> , 2012, 42, 764-766.	1.1	63
88	Risk factors for prediction of inadequate response to antiresorptives. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 817-824.	3.1	63
89	Role of serum FSH measurement on bone resorption in postmenopausal women. <i>Endocrine</i> , 2012, 41, 302-308.	1.1	49
90	Results from a national survey on the management of primary hyperparathyroidism. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 957-63.	1.8	14

#	ARTICLE	IF	CITATIONS
91	Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer. <i>Endocrinología Y Nutrición</i> (English Edition), 2011, 58, 487-491.	0.5	9
92	Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer. <i>Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición</i> , 2011, 58, 487-491.	0.8	9
93	Osteocalcin and atherosclerosis: A complex relationship. <i>Diabetes Research and Clinical Practice</i> , 2011, 92, 405-406.	1.1	6
94	Osteocalcin as a marker of metabolic risk in healthy postmenopausal women. <i>Menopause</i> , 2011, 18, 537-541.	0.8	36
95	The treatment of primary hyperparathyroidism. <i>IBMS BoneKEy</i> , 2011, 8, 362-369.	0.1	2
96	A nutritional intervention study with hydrolyzed collagen in pre-pubertal Spanish children: influence on bone modeling biomarkers. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2011, 24, 147-53.	0.4	9
97	Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease. <i>Aging Clinical and Experimental Research</i> , 2011, 23, 112-7.	1.4	15
98	Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor κ B in women with postmenopausal osteoporosis. <i>Menopause</i> , 2010, 17, 140-144.	0.8	14
99	Improvement of bone formation biomarkers after 1-year consumption with milk fortified with eicosapentaenoic acid, docosahexaenoic acid, oleic acid, and selected vitamins. <i>Nutrition Research</i> , 2010, 30, 320-326.	1.3	43
100	Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpressSR (OSTEOXPRESS Study). <i>Aging Clinical and Experimental Research</i> , 2010, 22, 419-426.	1.4	10
101	Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 27-32.	1.4	35
102	Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. <i>Maturitas</i> , 2009, 64, 188-192.	1.0	39
103	Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2008, 19, 87-94.	1.3	71
104	Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 416-421.	1.8	20
105	Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: A multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. <i>Clinical Therapeutics</i> , 2007, 29, 1937-1949.	1.1	23
106	Osteoporosis: informe del Grupo de Trabajo de Metabolismo Mineral de la SEEN. <i>Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición</i> , 2007, 54, 53-61.	0.8	1
107	Inhaled Steroids Do Not Decrease Bone Mineral Density But Increase Risk of Fractures: Data from the GIUMO Study Group. <i>Journal of Clinical Densitometry</i> , 2006, 9, 154-158.	0.5	32
108	Lactose Intolerance Revealed by Severe Resistance to Treatment with Levothyroxine. <i>Thyroid</i> , 2006, 16, 1171-1173.	2.4	43

#	ARTICLE	IF	CITATIONS
109	The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. <i>Osteoporosis International</i> , 2005, 16, 1368-1374.	1.3	83
110	Postmenopausal Women With Colles' Fracture Have Lower Values of Bone Mineral Density Than Controls as Measured by Quantitative Ultrasound and Densitometry. <i>Journal of Clinical Densitometry</i> , 2005, 8, 430-435.	0.5	5
111	Susceptibility for Postmenopausal Osteoporosis: Interaction Between Genetic, Hormonal and Lifestyle Factors. <i>Calcified Tissue International</i> , 2004, 75, 373-379.	1.5	18
112	Calcitonin Therapy in Osteoporosis. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 117-132.	1.8	72
113	Performance of quantitative ultrasound in the discrimination of prevalent osteoporotic fractures in a bone metabolic unit. <i>Bone</i> , 2003, 32, 571-578.	1.4	38
114	Quantitative Ultrasound Calcaneus Measurements: Normative Data and Precision in the Spanish Population. <i>Osteoporosis International</i> , 2002, 13, 487-492.	1.3	63
115	Performance of COL1A1 Polymorphism and Bone Turnover Markers to Identify Postmenopausal Women with Prevalent Vertebral Fractures. <i>Osteoporosis International</i> , 2002, 13, 506-512.	1.3	16
116	The contribution of IGF-I to skeletal integrity in postmenopausal women. <i>Clinical Endocrinology</i> , 2001, 55, 759-766.	1.2	32
117	Relation Between Vitamin D Insufficiency, Bone Density, and Bone Metabolism in Healthy Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1408-1415.	3.1	181
118	Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study. <i>Osteoporosis International</i> , 1999, 9, 461-468.	1.3	521
119	Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. <i>Hepatology</i> , 1998, 28, 695-699.	3.6	209
120	Methimazole-Induced Aplastic Anemia in Third Exposure: Successful Treatment with Recombinant Human Granulocyte Colony-Stimulating Factor. <i>Thyroid</i> , 1998, 8, 791-794.	2.4	20
121	Identification of Metabolic Bone Disease in Patients with Endogenous Hyperthyroidism: Role of Biological Markers of Bone Turnover. <i>Calcified Tissue International</i> , 1997, 61, 370-376.	1.5	18
122	Virilizing mature ovarian cystic teratomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 431, 149-151.	1.4	18
123	Effect of Tobacco Consumption on Bone Mineral Density in Healthy Young Males. <i>Calcified Tissue International</i> , 1997, 60, 496-500.	1.5	78
124	Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. <i>Clinical Endocrinology</i> , 1997, 47, 279-285.	1.2	64
125	Antiresorptive Therapy in Hyperthyroid Patients: Longitudinal Changes in Bone and Mineral Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1989-1994.	1.8	16
126	Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. <i>Calcified Tissue International</i> , 1996, 58, 316-319.	1.5	155

#	ARTICLE	IF	CITATIONS
127	Bone mass in androgen-insensitivity syndrome: Response to hormonal replacement therapy. <i>Calcified Tissue International</i> , 1995, 57, 94-96.	1.5	73
128	Bone mineral density, sex steroids, and mineral metabolism in premenopausal smokers. <i>Calcified Tissue International</i> , 1994, 55, 403-407.	1.5	48
129	Hyperinsulinemia in polycystic ovary syndrome: relationship to clinical and hormonal factors. <i>The Clinical Investigator</i> , 1994, 72, 853-7.	0.6	10
130	Letters to the Editors. <i>Clinical Endocrinology</i> , 1994, 40, 281-283.	1.2	1
131	Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 647-652.	1.8	6
132	Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. <i>European Journal of Endocrinology</i> , 1994, 130, 333-338.	1.9	25
133	Alterations in bone turnover in HIV-positive patients. <i>Infection</i> , 1993, 21, 220-222.	2.3	51
134	Bone mass in females with different thyroid disorders: influence of menopausal status. <i>Bone and Mineral</i> , 1993, 21, 1-8.	2.0	52
135	Effect of ketoconazole in the hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN) syndrome. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 786.	0.6	5
136	Dehydroepiandrosterone sulfate and other possible influencing factors that modulate sex hormone-binding globulin levels in the hirsute patient. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 42, 607-611.	1.2	5